Skip to Main Content

Paper Details

Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models.
J Clin Invest
1
2023
ADC, ARPC, ARPC models, ARPC tumors, B7H3, B7H3-ADC, DNA repair mutations, PBD, RB1, RB1 WT, RB1 deficiency, SLFN11, WT TP53, androgen, cancer, mPC, metastatic prostate cancer, patient, patients, prostate cancer, pyrrolobenzodiazepine, tumor
Author NameAffiliation
Eva Corey
Ilsa ColemanDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center
Peter S NelsonDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center
Peter S NelsonDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center
Brian J CapaldoCenter for Cancer Research, National Cancer Institute
Adam G SowalskyCenter for Cancer Research, National Cancer Institute
  • 1 - 6

Datasets

Release 1.2